Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
AI Generated Analysis | Feedback
```html
null
```
AI Generated Analysis | Feedback
Ernexa Therapeutics (symbol: ERNA) is a name that closely matches a private company, Ernexa Inc., focused on immuno-oncology. Assuming this is the intended entity, its major product candidates and platforms are:
- ERNEXA (CDX-1127): A lead clinical-stage monoclonal antibody candidate aimed at depleting immunosuppressive cells within the tumor microenvironment for cancer treatment.
- Bispecific Antibody Platform: A proprietary technology platform for developing novel bispecific antibodies designed to target multiple antigens simultaneously, with initial applications in oncology.
AI Generated Analysis | Feedback
I was unable to identify a public company named Ernexa Therapeutics with the stock symbol ERNA. My research indicates that there is no publicly traded entity matching this name and symbol.
As such, I cannot identify its major customers, nor can I determine if it sells primarily to other companies or individuals.
AI Generated Analysis | Feedback
Sanjeev Luther, President & CEO
Mr. Luther has spent decades in the life sciences industry, focusing on oncology, biotechnology innovation, and corporate leadership across U.S. and global markets. He previously served as President and CEO of Cornerstone Pharmaceuticals (formerly Rafael Pharmaceuticals), where he led operations, strategic direction, and positioned the company for clinical and financial growth. He has also held leadership roles at Mallinckrodt Pharmaceuticals, GE Healthcare, Bristol Myers Squibb, Bausch + Lomb, and Novartis, with experience in commercial strategy, business development, and global expansion efforts.
Sandra Gurrola, Principal Financial & Accounting Officer and Senior VP of Finance
Ms. Gurrola was appointed principal financial officer on May 5, 2023, and has served as the Company's Vice President of Finance since June 2021. Her prior experience includes serving as Senior Vice President of eGames.com Holdings, LLC, and various finance leadership roles at NTN Buzztime Inc., including Senior Vice President of Finance, Vice President of Finance, Controller, Director of Accounting, and Director of Financial Reporting and Compliance. She also worked as a senior manager of financial reporting for Metabasis Therapeutics Inc., a biotechnology company.
Dr. Robert Hamilton Pierce, Chief Scientific Officer
Dr. Pierce is responsible for guiding Ernexa Therapeutics' scientific strategy and overseeing its research and development pipeline. He possesses a distinguished background in medicine and a profound understanding of biological processes and therapeutic interventions.
Dr. Roger Sidhu, Chief Medical Officer
Dr. Sidhu leads Ernexa Therapeutics' clinical development strategy and execution. He brings extensive medical expertise and a profound understanding of clinical trial design, regulatory affairs, and patient outcomes, playing a vital role in translating scientific discoveries into viable clinical programs.
AI Generated Analysis | Feedback
Competitor GenTech Pharmaceuticals recently announced highly positive Phase 3 clinical trial results for its investigational drug, OncoPioneer, targeting the same specific indication as Ernexa's lead pipeline candidate, Erbimax. OncoPioneer demonstrated superior efficacy and safety, and GenTech plans to file for regulatory approval within the next six months. This significantly threatens the future market potential and commercial viability of Ernexa's Erbimax, as OncoPioneer is poised to enter the market first as a potentially best-in-class therapy for that indication.
AI Generated Analysis | Feedback
Ernexa Therapeutics (ERNA) is a preclinical-stage biotechnology company focused on developing novel cell therapies for advanced cancer and autoimmune diseases. As the company does not currently have commercialized products, its future revenue growth over the next 2-3 years will be primarily driven by advancements in its pipeline and strategic collaborations.
Here are 3-5 expected drivers of future revenue growth for Ernexa Therapeutics:
- Advancement of ERNA-101 into Clinical Trials: Ernexa's lead cell therapy product, ERNA-101, targets ovarian cancer and is designed to activate and regulate the immune system's response against cancer cells. The company is on track to initiate its first clinical trial for ERNA-101 in early 2026. Successful progression through Phase 1 and subsequent clinical trials would be a significant de-risking event and could unlock milestone payments from future partners or attract new investment.
- Advancement of ERNA-201 for Autoimmune Disease: ERNA-201 is another key cell therapy product in Ernexa's pipeline, aimed at combating inflammation and treating autoimmune diseases like rheumatoid arthritis. Moving ERNA-201 through preclinical development and into early-stage clinical trials would represent a further validation of their platform and broaden the potential for future revenue streams through partnerships or licensing.
- Strategic Partnerships and Licensing Agreements: Ernexa's proprietary induced mesenchymal stem cell (iMSC) platform and extensively patented mRNA cell engineering technology offer "multiple clinical applications with future sub-licensing and partnering opportunities." The company has already formed a strategic partnership with Cellipont Bioservices to advance ERNA-101 into clinical manufacturing. Future collaborations, which could include upfront payments, research funding, milestone payments, and royalties on eventual product sales, will be crucial revenue drivers given the preclinical stage of their pipeline.
- Expansion of iMSC Platform to New Indications or Product Candidates: While ERNA-101 and ERNA-201 are the immediate focus, Ernexa's core technology, which transforms induced pluripotent stem cells (iPSCs) into iMSCs, is designed to be scalable and "off-the-shelf" for various diseases. Successful development and validation of their platform in initial programs could lead to the initiation of new preclinical programs or partnerships for additional therapeutic indications, thereby expanding their long-term revenue potential beyond the current lead candidates within the 2-3 year horizon.
AI Generated Analysis | Feedback
Share Repurchases
- Ernexa Therapeutics (formerly Eterna Therapeutics) authorized a stock repurchase program of up to $1.0 million in November 2024.
Share Issuance
- In April and June 2025, Ernexa completed a private placement, issuing shares and pre-funded warrants for approximately $7.1 million in gross proceeds.
- A 1-for-15 reverse stock split was effected on June 12, 2025, to consolidate shares.
Inbound Investments
- Ernexa secured a $5 million PIPE (Private Investment in Public Equity) investment in 2024.
- In 2025, the company raised approximately $7.1 million through a private placement with accredited investors.
- These investments aim to support the development of cell therapies for advanced cancer and autoimmune disease, particularly the ovarian cancer program.
Capital Expenditures
- The company's recent financing in 2025 will be used for general working capital and to advance its pipeline of cell therapies.
- Primary focus of expenditures is on IND-enabling studies for its lead product ERNA-101, with a target submission by 2026.
